Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Fineline Cube May 8, 2026
Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Fineline Cube May 8, 2026
Company Drug

Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment

Fineline Cube May 8, 2026
Company Drug

Eli Lilly Launches New Formula of Taltz in China with Reduced Injection Site Pain

Fineline Cube May 31, 2024

Eli Lilly and Company (NYSE: LLY), a leading pharmaceutical company in the U.S., has announced...

Company Deals

TÜV Partners with Lancy Co., Ltd’s BRAVOU to Enhance Medical Aesthetics Services in China

Fineline Cube May 31, 2024

Technischer Überwachungs-Verein (TÜV), a Germany-based international independent third-party testing, inspection, and certification organization, has entered...

Company Deals

Burning Rock Expands Companion Diagnostics Partnership with Bayer for Precision Oncology in China

Fineline Cube May 31, 2024

Burning Rock Ltd (NASDAQ: BNR), a China-based medical technology company, has announced another partnership in...

Company Deals

Parexel Partners with Ruijin Hospital Hainan Subsidiary to Enhance Real-World Evidence in Drug Development

Fineline Cube May 31, 2024

Parexel, a U.S.-based contract research organization (CRO), has entered into a partnership with Shanghai Ruijin...

Company Drug

Hengrui Pharmaceuticals Advances Two Drug Candidates Following NMPA Clinical Trial Green Lights

Fineline Cube May 31, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Drug

JW Therapeutics Presents Positive Clinical Data for Carteyva in SLE at EULAR 2024

Fineline Cube May 31, 2024

JW Therapeutics (HKG: 2126), a biopharmaceutical company based in China, has presented new clinical data...

Company Drug

Akeso Inc.’s Ivonescimab Shows Positive Interim Analysis in Phase III NSCLC Study

Fineline Cube May 31, 2024

Akeso Inc. (HKG: 9926), a biopharmaceutical company based in China, has announced positive interim analysis...

Company Deals

Lucy Therapeutics Boosts CNS Disease Research with USD 12.5 Million in Additional Financing

Fineline Cube May 31, 2024

Lucy Therapeutics Inc., a U.S.-based developer of small-molecule drugs for central nervous system (CNS) diseases,...

Company Drug

Laekna Therapeutics Initiates Phase III Trial for Breast Cancer Candidate LAE002 in Combination with Fulvestrant

Fineline Cube May 30, 2024

Laekna Therapeutics Shanghai Co., Ltd, a biopharmaceutical company based in China, has announced the enrollment...

Company

Merck KGaA Launches Construction on Largest Asia-Pacific Investment with South Korean Bioprocessing Plant

Fineline Cube May 30, 2024

Merck KGaA (ETR: MRK), the German science and technology company, has commenced construction on a...

R&D

Shanghai Research Team Achieves Global First in Treating Type 2 Diabetes with Stem Cell Therapy

Fineline Cube May 30, 2024

A groundbreaking study out of Shanghai has made a significant stride in diabetes treatment. A...

Company Deals

Johnson & Johnson to Acquire Atopic Dermatitis Therapy NM26 in $1.25 Billion Deal

Fineline Cube May 30, 2024

Johnson & Johnson (J&J; NYSE: JNJ), a global healthcare giant, has entered into a definitive...

Company Drug

Jiangsu QYuns Therapeutics Initiates Phase III Trial for Skin Disease Candidate QX005N

Fineline Cube May 30, 2024

Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509), a biopharmaceutical company based in China, has announced...

Company Deals

HuidaGene and Synthego Form Strategic Partnership for CRISPR-Based Therapies

Fineline Cube May 30, 2024

HuidaGene (Shanghai) Biotechnology Co., Ltd, a clinical-stage biotechnology company based in China, has entered into...

Company Drug

Wanbangde’s Huperzine A Earns Orphan Drug Status from FDA for Treating Neonatal Brain Injury

Fineline Cube May 30, 2024

Wanbangde New Building Materials Co., Ltd (SHE: 002082), a company operating in China, has announced...

Company Drug

Zelgen Biopharmaceuticals Gets NMPA Approval for Jacktinib Vitiligo Trial in Adolescents and Adults

Fineline Cube May 30, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has received...

Company Drug

Hengrui Pharmaceuticals’ Vitiligo Treatment SHR0302 and Diabetes Drug HRS9531 Get Green Light from China’s NMPA

Fineline Cube May 30, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading biopharmaceutical company based in China, has...

Company Deals

Fosun Pharma Rumored to Fully Acquire Subsidiary Henlius Pharmaceutical, Shares Suspended

Fineline Cube May 30, 2024

Rumors are circulating, as reported by Bloomberg citing insiders, that Shanghai Fosun Pharmaceutical (Group) Co.,...

Company Drug

Amgen’s Bkemv Becomes First Biosimilar to Challenge AstraZeneca’s Soliris with FDA Approval

Fineline Cube May 30, 2024

Amgen Inc. (NASDAQ: AMGN), a leading biopharmaceutical company, has been granted regulatory approval by the...

Company Drug

Full-Life Technologies Receives FDA Green Light for ²²⁵Ac-FL-020 Clinical Study in mCRPC

Fineline Cube May 30, 2024

Full-Life Technologies Ltd, a globally integrated radiotherapeutics company with a presence in Belgium, Germany, and...

Posts pagination

1 … 348 349 350 … 662

Recent updates

  • China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban
  • Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies
  • Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort
  • Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance
  • Zai Lab Reports Q1 2026 Revenue Decline Amid Zejula Impact from Centralized Procurement, Offset by Xacduro Growth
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Company

Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.